Literature DB >> 8105167

Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis.

J P Teare1, D Sherman, S M Greenfield, J Simpson, G Bray, A P Catterall, I M Murray-Lyon, T J Peters, R Williams, R P Thompson.   

Abstract

In early hepatic fibrosis, increased amounts of type III collagen are deposited. Persistently high serum concentrations of aminoterminal type III procollagen propeptide (PIIIP) correlate with the activity of the fibrogenic process. Another index for the detection of fibrosis, the PGA index, combines the prothrombin time, gamma-glutamyl transpeptidase activity, and serum apolipoprotein A1 concentration (the latter falls with progressive fibrosis). We compared PIIIP measurements and PGA index in patients with various histological forms of alcoholic liver disease (104), primary biliary cirrhosis (38), and chronic B virus hepatitis (27), and in healthy age-matched controls (30). The ability of each test to identify correctly patients with fibrosis or cirrhosis was assessed with receiver operating curves. The PGA index was much higher in all groups of patients with alcoholic liver disease than in controls (p < 0.0001). PIIIP concentrations were also substantially higher than in controls (p < 0.05 for fatty liver, p < 0.0001 for all other groups), especially in the group with alcoholic hepatitis and cirrhosis. For the detection of cirrhosis the PGA was 91% sensitive and 81% specific and the PIIIP concentration was 94% sensitive and 81% specific. The two tests combined had 85% sensitivity, but 93% specificity. Among patients with primary biliary cirrhosis, both PGA index and PIIIP concentration correlated well with the severity of the disease, determined by the Mayo score (r = 0.72 and 0.66 respectively). The combined tests were 96% sensitive for the detection of fibrosis. All patients with chronic B virus hepatitis had raised PGA and PIIIP values in comparison with controls (p < 0.0001) but there were no differences between subgroups. Substantially raised PIIIP concentrations thus identify the subgroup of alcoholic patients with both hepatitis and cirrhosis. The combination of PGA index and PIIIP concentration may be useful for targeting treatment with antifibrotic drugs and to reduce the need for liver biopsy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105167     DOI: 10.1016/0140-6736(93)91946-j

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  Non-invasive diagnosis of liver fibrosis and cirrhosis.

Authors:  Yoav Lurie; Muriel Webb; Ruth Cytter-Kuint; Shimon Shteingart; Gerardo Z Lederkremer
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

Authors:  Hye Ran Yang; Hae Ryoung Kim; Myung Jin Kim; Jae Sung Ko; Jeong Kee Seo
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

3.  Low plasma apolipoprotein A-I level is not a reliable marker of fibrosis in children with chronic hepatitis B.

Authors:  Mukadder-Ayse Selimoglu; Rasit-Vural Yagcl; Gül Yüce
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

4.  Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist.

Authors:  Balsam El Ghoul; Tarek Squalli; Aude Servais; Caroline Elie; Vannary Meas-Yedid; Christine Trivint; Jill Vanmassenhove; Jean-Pierre Grünfeld; Jean-Christophe Olivo-Marin; Eric Thervet; Laure-Hélène Noël; Dominique Prié; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

5.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

6.  The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Authors:  Maximilian Schöniger-Hekele; Christian Müller
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

Review 7.  From fatty liver to fibrosis: a tale of "second hit".

Authors:  Metin Basaranoglu; Gökcen Basaranoglu; Hakan Sentürk
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

Review 8.  Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage.

Authors:  Pamela Valva; Daniela A Ríos; Elena De Matteo; Maria V Preciado
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

9.  The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.

Authors:  Mette J Nielsen; Anders F Nedergaard; Shu Sun; Sanne S Veidal; Lise Larsen; Qinlong Zheng; Charlotte Suetta; Kim Henriksen; Claus Christiansen; Morten A Karsdal; Diana J Leeming
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

10.  A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease.

Authors:  Joe Gray; Dipankar Chattopadhyay; Gary S Beale; Gillian L Patman; Luca Miele; Barry P King; Stephen Stewart; Mark Hudson; Christopher P Day; Derek M Manas; Helen L Reeves
Journal:  BMC Cancer       Date:  2009-08-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.